Skip to main content

Modelling Neuron-Glia Networks into a drug discovery platform for Pain Efficacious Treatments - Sofia ref.: 116072

Objective

Chronic Neuropathic Pain is frequently associated with peripheral nerve injury or disease. Peripheral injury activates both neuronal and glial components of the peripheral and central cellular circuitry. While it is widely known that the subsequently altered interactions between neurons and glial cells contribute to pain development and to its chronification, the underlying mechanisms are poorly understood. Developing mechanism-based therapies targeting neuron-glial interactions to treat chronic pain will be crucial for improving the quality of life of many patients. Hence the development of novel therapeutic solutions represents a major challenge that demands a multi-disciplinary approach to decipher and understand pathological mechanisms and to translate them into predictive tools for drug development. The NGN-PET consortium addresses this challenge by forming a highly interdisciplinary team that builds upon expertise in areas of academic research on pain
mechanisms, industrial knowhow on human stem cell-based tool development, HTS technologies and drug discovery. To achieve its goal we will develop preclinical model systems and assays which recapitulate the human in vivo situation and which can be interrogated for the identification, validation of molecular targets and the development new treatments. A focus of the project will be chemotherapy induced NP and the interplay between nociceptors, microglia and Schwann cells. NGN-PET will carefully characterize rodent in vivo and in vitro models to identify these mechanisms, and will develop rat and human iPSCs based in vitro systems of neuron-glial co-cultures that can be interrogated for targets and used for compound identification and validation. NGN-PET will thus pose the basis for the translation of these model systems into high throughput screening platforms for pharmaceutical research and drug discovery.

Coordinator

AXXAM SPA
Net EU contribution
€ 443 000,00
Address
Via Meucci 3
20091 Bresso Milano
Italy

See on map

Region
Nord-Ovest Lombardia Milano
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00

Participants (5)

LIFE AND BRAIN GMBH
Germany
Net EU contribution
€ 443 000,00
Address
Venusberg-campus 1
53127 Bonn

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Nordrhein-Westfalen Köln Bonn, Kreisfreie Stadt
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
KING'S COLLEGE LONDON
United Kingdom
Net EU contribution
€ 450 000,00
Address
Strand
WC2R 2LS London

See on map

Region
London Inner London — West Westminster
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN
Germany
Net EU contribution
€ 164 000,00
Address
Markwiesenstrasse 55
72770 Reutlingen

See on map

Region
Baden-Württemberg Tübingen Reutlingen
Activity type
Research Organisations
Non-EU contribution
€ 14 000,00
ESTEVE PHARMACEUTICALS, SA
Spain
Net EU contribution
€ 0,00
Address
Passeig De La Zona Franca 109, 4a Planta
08038 Barcelona

See on map

Region
Este Cataluña Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 793 000,00
GRUNENTHAL GMBH
Germany
Net EU contribution
€ 0,00
Address
Zieglerstrasse 6
52078 Aachen

See on map

Region
Nordrhein-Westfalen Köln Städteregion Aachen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 743 000,00